This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Inflammation				
Allergy	Transforming growth factor- β 1 (TGFB1); transforming growth factor- β receptor 1 (TGFB1; ALK5); TGFB2 (TGF β -RII)	<p>Studies in human samples suggest inhibiting TGFB1 or TGFB2 could help treat allergy-related conditions. In 58 patients with Loeys-Dietz syndrome (LDS), a monogenic condition associated with mutations in the genes encoding TGFB1 or the TGFB1 and TGFB2 receptors, incidences of allergy-related conditions including asthma, food allergy, rhinitis, eczema and functional gastrointestinal disorders were increased compared with those in the general population. In patient samples, TGFB1 and TGFB2 signaling activity and markers of allergies were greater than those in healthy controls. Next steps could include testing TGFB1 inhibitors in allergy models.</p> <p>Eli Lilly and Co.'s LY2157299, an inhibitor of TGFB1 and TGFB2, is in Phase II testing to treat various cancers.</p> <p>SciBX 6(33); doi:10.1038/scibx.2013.895 Published online Aug. 29, 2013</p>	Patent and licensing status unavailable	<p>Frischmeyer-Guerrero, P.A. <i>et al. Sci. Transl. Med.</i>; published online July 24, 2013; doi:10.1126/scitranslmed.3006448</p> <p>Contact: Harry C. Dietz, The Johns Hopkins University School of Medicine, Baltimore, Md. e-mail: hdietz@jhmi.edu</p>